De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression
N. K. Tangudu, R. Buj, H. Wang, J. Wang, A. R. Cole, A. Uboveja, R. Fang, A. Amalric, P. Sajjakulnukit, M. A. Lyons, K. Cooper, N. W. Hempel, N. W. Snyder, C. A. Lyssiotis, U. R. Chandran, K. M. Aird
This study identifies de novo purine metabolism as a vulnerability in cancers with low p16 expression, showing sensitivity to anti-folate drugs like methotrexate.
bioRxiv · Jul 15, 2023Cancer Biology